

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) **MAIL STOP AMENDMENT**
Nicholas Bodor et al.) Group Art Unit: 1623
Application No.: 10/551,205) Examiner: JONATHAN S LAU
Filing Date: November 14, 2006) Confirmation No.: 4092
Title: ORAL FORMULATIONS OF)
CLADRIBINE)
)

**SIXTH
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a Sixth Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.

- No additional fee for submission of an IDS is required.
- The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A statement under 37 C.F.R. § 1.17(p) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge _____ to Deposit Account No. 02-4800 for the fee due.
- Charge \$ 180 to credit card for the fee due. Form PTO-2038 is attached.
- The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800.

Respectfully submitted,

BUCHANAN INGERSOLL AND ROONEY PC

Date December 16, 2009

By: Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26254

Customer No. 21839
703 836 6620